Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
ChemoMetec A/S Maintains FY 2012 EBIT and Revenue Guidance
ChemoMetec A/S announced that it has maintained its previously announced fiscal year 2012 financial guidance. The Company still expects to report fiscal year 2012 EBIT in a range of between DKK 9 million and DKK 11 million. The Company also still expects to report fiscal year 2012 revenue in a range of between DKK 42 million and DKK 44 million.
Latest Key Developments in Medical
- Essilor International SA Acquires Eight Businesses
- MIT Capital Inc Proposes To Acquire Meade Instruments Corp For $3.65 Per Share In Cash
- FDA Grants Prostate IDE Approval For Angiodynamics Inc's NanoKnife System
- Urban Ag Corp Announces It Has Entered Into The Final Stages Of Negotiations To Acquire Contractor Currently Generating $4,500,000 In Revenues
- Share this
- Link this
- Digg this
Follow Reuters